The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …

Abstract Purpose of Review Over the last ten years, the treatment of psychosis has seen a
near explosion of creative development in both novel agents and new delivery modalities …

Formulating aqueous suspensions is an attractive strategy to incorporate poorly water-
soluble drugs, where the drug release can be tailored to maintain desired release profiles of …

Schizophrenia is a chronic medical condition with periods of remission and relapses over a
patient's lifetime. Antipsychotic medications represent the mainstay of treatment for this …

Background: The use of therapeutic drug monitoring (TDM) to guide treatment with long-
acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of …

Introduction: In this review, the authors discuss the role of long-acting injectable
antipsychotics (LAIs) for schizophrenia, focusing on the effectiveness and new perspectives …

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly
used in clinical practice in Psychiatry due to the high variability regarding response and side …

Long-acting injectable (LAI) neuroleptics constitute an effective therapeutical alternative for
individuals suffering from persistent mental illness. These injectable pharmaceuticals help …

Schizophrenia is a severe mental illness causing a high degree of disability. First-and
second-generation antipsychotics (FGAs and SGAs) represent key resources for its acute …